CA2216382A1 - Storage stable hemoglobin solutions - Google Patents

Storage stable hemoglobin solutions Download PDF

Info

Publication number
CA2216382A1
CA2216382A1 CA002216382A CA2216382A CA2216382A1 CA 2216382 A1 CA2216382 A1 CA 2216382A1 CA 002216382 A CA002216382 A CA 002216382A CA 2216382 A CA2216382 A CA 2216382A CA 2216382 A1 CA2216382 A1 CA 2216382A1
Authority
CA
Canada
Prior art keywords
hemoglobin
composition
oxygen
storage stable
solution
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002216382A
Other languages
French (fr)
Inventor
Bruce A. Kerwin
Douglas L. Looker
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Baxter Biotech Technology SARL
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2216382A1 publication Critical patent/CA2216382A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/795Porphyrin- or corrin-ring-containing peptides
    • C07K14/805Haemoglobins; Myoglobins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid

Abstract

The present invention relates to storage stable hemoglobin solutions which contain partially deoxygenated hemoglobin and surprisingly low amounts of reducing agents. Methods for preparing such storage stable hemoglobin solutions are also provided as well as a system for storing the solutions.

Description

W 096/34889 PCTrUS96/06080 STORAGE STABLE ~EMOGLOBIN SOLUTIONS

FIELD OF INVENTION

The present invention relates to storage stable hemoglobin solutions, and more particularly to solutions cont~ining partially deoxygenated hemoglobin and reducing agents.

BACKGROUND OF THE INVENTION

The oxygen carrying portion of the red blood cell is hemoglobin, a 15 tetrameric protein molecule composed of two identical alpha globins (a1, a2),two i~entical beta globins (~ r ,132) and four heme molecules. A heme molecule is incorporated into each of the alpha and beta globins to give alpha and beta subunits. Heme is a macrocyclic organic molecule that contains an iron atom at its center; each heme can combine reversibly with one ligand molecule, for 20 example oxygen. In a hemoglobin tetramer, each alpha subunit is associated with a beta subunit to form two stable alpha/beta dimers, which in turn associaL-e to form the tetramer (a homodimer). The subunits are noncovalently associat:ed through Van der Waals forces, hydrogen bonds and salt bridges.
In the unlig~n~led state (deoxygenated or "deoxy") state, the four 25 subunits form a quaternary structure known as "T" (for "tense") state. Duringligand binding, the al~1 and a2~2 interfaces remain relatively fixed while the al~2 and a2,Bl interfaces exhibit considerable movement. When a ligand is bound ~o the hemoglobin molecule, the globins move with respect to each other, and as a result intersubunit distances are increased relative to the 30 deoxygenated distances. Thus, when a ligand is bound at the heme groups, the molecule assumes the "relaxed" or "R" quaternary structure, the W O 96/34889 PCTrUS96/06n80 thermodynamically stable form of the molecule when lig~nf1.s are bound at three or more hemes.
T.ig~ncl~, particularly oxygn, bind reversibly to the reduced form of the iron (ferrous, Fe+2) in the heme. When the iron in the heme is oxi~li7pd to 5 Fe+3 (the ferric form of iron), oxygen and some other ligands cannot bind to the iron of the heme and the hemoglobin is non-functional in terms of oxygen transport. The iron in the heme groups may be oxidized in a number of fashions. For example, the iron may oxidize through a pathway mediated by binding of a water molecule at the heme iron to produce methemoglobin 10 ("autoxidation"). Autoxi~l~hon can be enhanced by the presence of trace metals in solution. Methemoglobin can also be produced as a result of direct oxidation by rh.omir~lc with higher redox ~o~ , such as ferricyanide, or by indirect oxidation by reducing agents through a hydrogen peroxide me~ terl pathway (Castro, C.E. et al., in: Biochemical and Clinical Aspects of Hemoglobin Abnormalities, A~ mic Press, Inc., pp 495-503,1978). Furthermore, deoxyhemoglobin can be oxidized to methemoglobin by rh~mi~ such as ferricyanide even in the absence of oxygen. The ~-olei~- itself may be oxidized as well, without concommittant oxidation of the iron in the heme groups. For example, hemoglobin may be oxidatively denatured by chemicals such as 20 hydrazine without going through a methemoglobin intermediate. (see Bunn, H.F. and Forget, B.G. Hemoglobin: Molecular Genetic and ~'linic~l Aspects, W.B. Saunders Company, Phil~tielphia, pp 634 662 for review).
However produced, methemoglobin is a non-functional form of hemoglobin that cannot bind oxygen or carbon monoxide and shows 25 significantly altered nitric oxide binding characteristics. Methemoglobin molecules are vulnerable to accelerated degradation due to hemichrome formation, heme loss, precipitation, reaction with hydrogen peroxide to form toxic radicals and the like.

W 096/3~889 PCT~US96/06080 In addition to the reduction of funchon~lity of a hemoglobin solution by the formation of methemoglobin, the y~oleill portions of the hemoglobin molecule can be modified and altered by oxidative damage. For example, the oxidation of the iron of the heme results in the production of hydrogen peroxide (Watkins, J.A. Bioc. Biophys. Res. Comm. 132: 742-748, 1985) as well assuperoxide (Thillet, J. and Michelson, A.M., Free Rad. Res. Comm. 1: 89-100, 1985). These activated oxygen species can then damage the hemoglobin ~oleill, for example, by causing polymerization of the Jnc-lecllle (Thillet, J., supra) or by damaging individual amino acids and thereby disrupting tertiary structure (Stefek, R. P. and Thomas, M.J., Free Rad. Res. Comms. 12-13: 489~97, 1991).
These changes can result in increased immunogenicity (Riechlin, M., Adv.
Immunol. 20: 71-132, 1975; Noble, R.W. et al. Bioc. 11: 3326-3332, 1972).
Ultimately, damage resulting from activated oxygen species, irrespective of source, may lead to oxidative denaturation of the mclecllle and its precipitation. Therefore, during storage of hemoglobin solutions, the avoidance of oxidation, whether of the protein itself or of the heme groups within the ~roleill, is ner~ss~ry to m~int~in functionality and the tertiary andquaternary structure of hemoglobin in solution and to limit immunogenicity.
It has long been known that hemoglobin solutions form methemoglobin more slowly if stored under deoxygenated conditions rather than oxygenated condiLions (Antonini and Brunori, Hemoglobin and Mvoglobin in Their Reactions with Ligands, North Holland Publishing Company, Amsterdam 13-39, 1971; Di Iorio, E.E., Meth. Enzymol. 76: 57-72, 1981). However, preservationof hemoglobin under deoxygenated conditions poses significant technical difficulties (Di Iorio, E.E., Meth. Enzymol. 76: 57-72, 1981), or requires the addition of potentially toxic chemicals. Moreover, the choice of exogenous chemical agents has been extremely difficult since these additives can act as oxidants or reductants, depending on the conditions of the solution and unpredictable protein/agent interactions (Akers, M.J. J. Parent. Sci. Tech. 36:

CA 022l6382 l997-09-24 222 - 228, 1982). In the case of hemoglobin solutions, the choice of an exogenous chemical agent that will act as a reductant is further complicated by the fact that not all reducing agents can reduce hemoglobin, and some reducing agents may act as oxidants in a given hemoglobin formulation (Eyer, P., Mol. Pharmacol.
11: 326-334, 1975; Kikugawa, K. Chem. Pharm. Bulletin 29: 1382-1389, 1981;
Stratton, L.P. Hemoglobin 12: 353-368, 1988). If the exogenous chemical does act to reduce methemoglobin formation in solution, there may be unexpected side reactions that can affect the protein structure (Antonini and Brunori, Hemoglobin and Myoglobin in Their Reactions with Ligands, North HC~11An~1 Publishing Company, Amsterdam 13-39, 1971).
In order to reduce or .olimin~te the need for exogenous reducing agents during storage, Nho (PCT publication WO 92/08478) ~lesignell an apparatus which allowed the rapid deoxygenation of hemoglobin solutions. Hemoglobin solutions were deoxygenated by p~ssing the solution through one side of a gas exchange device and passing an inert gas, nitrogen, on the other side of a gas permeable membrane. The hemoglobin was arculated until it was at least 90%
deoxygen~te~l- No exogenous red~lct~nts were added to the hemoglobin solution; oxidation, although not completely eliminated, was slowed by careful removal of oxygen in the hemoglobin solution. Thus there was no introduction of chemical reductants which might elicit unforeseen biological responses when used in pharmaceutical formulations, or which might react with the hemoglobin itself in an unpredictable fashion.
A different approach to the storage of hemoglobin solutions was described by Kandler, R. L. and J. C. Spicuzza (US Patent 5,352,773 and PCT
publication WO 92/02239). They utilized the intrinsic ability of a purified di-aspirin crosslinked hemoglobin solution to "auto-reduce" in the absence of any exogenous chemical reductants. In their solutions, methemoglobin concentrations were reduced by storing the solutions in overwrapped, oxygen impermeable containers. Some of these overwrapped cont liners contained W 096/34889 PCTrUS96/06080 oxygen scavenging pouches placed between the overwrap and the inner container. Methemoglobin concentrations as high as 50% could be reduced to levels as low as 1.5% by storage alone as long as oxygen was rigorously exduded from the containers during the storage of the solution. This methodology did 5 not depend on whether or not the initial solution was deoxygenated prior to storage. However, even though this methodology did not require the addition of exogenous reducing agents, the material was held for long periods of time to ensure methemoglobin was reduced to dinically acceptable levels, and/or it was held at relatively high temperatures. E~Pnlle~l storage or storage at 10 elevated temperatures might result in modifications of the hemoglobin structure or growth of microorg~ni~ms if inadequately sterilized.
Deoxygenation of hemoglobin solutions alone may not provide sufficient stability to the hemoglobin solutions to allow for long term storage,especially storage at room temperature. For example, DeVenuto (DeVenuto, F., T. Lab. Clin. Med. 92: 946-952, 1978) found that deoxygenated hemoglobin solu~ions showed more rapid methemoglobin formation than comparable solutions stored in the presence of oxygen. Moreover, he was not able to demonstrate any solution that showed stability at room temperature.
Ascorbate (ascorbic acid or vitamin C) has been commonly used both in 20 pharmLaceutical compositions and as a reagent to scavenge oxygen or act as anantioxidant in hemoglobin compositions. As a pharmaceutical, ascorbate has been administered directly to treat methemoglobinemia in vivo (Kiese, M.
Methemoglobinemia: A Comprehensive Treatise, CRC Press, Inc., Cleveland, Ohio, pg. 23, 1974; Deeny, J., et al., Br. Med. T. 1: 721-723, 1943). Ascorbate has 25 been used as a preservative and a stabilizer in many protein solutions, particularly proteins derived from blood products. For example, G.P.
Wiesehahn et al. (US Patent 4,727,027) described the decontamination of solutions of biologically active proteins derived from blood or blood components, particularly Factor VIII, by photodecontamina ion. They W O 96/3~889 PCTrUS96/06080 stabilized solutions of Factor VIII prior to photo~lecont~mination by deoxygenating the solutions either by the ~ ition of high concentrations of oxygen scavengers, such as 10 mM ascorbate, by flushing with inert gases, or both addition of oxygen scavengers and flushing with inert gas. O~Lell,er et al.(PCT publication WO 94/26286) also describe a stabilized, deoxygenated formulation of factor VIII augmented with antioxidants such as glllt~thione, acetylcysteine, methionine, tocopherol, butyl hydroxy toluene, butyl hydroxy anisole or phenolic compounds. Although these antioxidants are suitable for use at low doses and are thus a~lo~liate for the small dosage volumes of Factor vm, many of these antioxidants can be toxic at high doses and hence are not appropriate for use in formlll~tions where high volumes of a therapeutic, for example, hemoglobin, might be administered. In addition, the application is silent with respect to the interaction of the antioxidants and hemoglobin. Itis of note that Osterber et al. report that the ~ on of ascc~lLJale to a deoxygenated solution of Factor VIII resulted in reduced Factor VIII stability.
As early as the 1940's, high conc~ lions of ascorbate were used to reduce methemoglobin in hemoglobin compositions (Gibson, Q.H., Bioc. T. 37:
615-618, 1943~. However, the interaction of ascorbate and hemoglobin have been unpredictable. For example, Kikugawa et al. (Kikugawa, K. et al., Chem.
Pharm. Bull. 29: 1382-1389, 1981) noted that ascorbate acted as a prooxidant, infact enhancing oxiri~tion, when added to oxygenated formulations of hemoglobin. Kramlova et al. (Kramlova, M. et al., Haematologia 10: 365-371, 1976) and Stratton et al., supra, suggested that addition of ascorbate to hemoglobin solutions also resulted in enhanced oxidation rather than protection from oxidation.
Ascorbate at relatively high concentrations has been used with some success to stabilize deoxygenated hemoglobin solutions. For example Bonhard et al. (US Patent 4,m,244) used ascorbate as an oxygen scavenger in a hemoglobin solution prior to crosslinking deoxygenated hemoglobin. They W O96/3q889 PCT/US96/06080 emphasized the need to use high levels of ascorbate (at least 4 moles of ascorbic acid per mole of hemoglobin) to ensure that all oxygen was scavenged in the hemoglobin solution. Kothe et al. (Kothe, N., Eichentopf, B. and Bonhard, K.
Surg. Gvn. Obst. 161: 563-569 1985) also used ascorbate to stabilize a 5 deoxygenated hemoglobin solution. These authors used 5.45 mM ascorbate in a 8.5 gm/dl hemoglobin solution (~ 4 moles ascorbate per mole of hemoglobin) and reported no significant formation of methemoglobin in the hemoglobin formlllAtion after storage at 4~C for one year. Clerc et al. (Clerc, Y. et al., Service de Santé des Armées Trav. Scient. 8: 211, 1987) reported similar low levels of 10 methemoglobin formation in a formulation based on the Kothe solution (4:1 molar ratio ascorbate to hemoglobin) during storage for 11 months at 4~C.
Kikugawa et al., supra, reported that dilute (250 mg/dl) deoxygenated hemoglobin solutions treated with 5 mM ascorbate (~ 13:1 molar ratio asco,L,a~e to hemoglobin) were stable for the 60 minutes of their study. Long term 15 stability of deoxygenated ascorbate con~ining solutions was not ~ sed by these authors. Nho et al. (U.S. Patent 5,234,903) followed methemoglobin formation in a 5 - 6 gm/dl deoxygenated bovine hemoglobin solution and found that 30 mM cysteine was 5 times more effective for the ~leve~LLion of methemoglobin formation than the same amount of ascorbate (~35:1 molar 20 ratio ascorbate: hemoglobin). Moreover, the addition of ascorbate to their hemoglobin formulation resulted in significant release of free iron. Tn-leell, Estep discussed the requirement that reductants that are added to hemoglobin solutions must have redox potenh~l~ higher than ascorbate to n~int~in these solutions under deoxygenated conditions; ascorbate is simply not sufficiently 25 reducing to maintain the deoxygenation of hemoglobin solutions (Estep, T.N.
US Patent, 4,861,867). Note that all compositions that have used ascorbate as anantioxidant or an oxygen scavenger have used at least a 4:1 molar ratio of ascorbate to hemoglobin.

W 096/3~889 PCT/US96/06080 Storage of previously known hemoglobin formulations at room temperature has proven probl~m~tic (Keipert, P. E. and Chang, T.M.S., Biomat.
Art. Cells Art. Org., 16: 185-196, 1988; Christensen, S.M. et al., T. Bioc. Biophys.
Meth. 17: 143-154, 1988; Moore, G.L. etal., Artif. Organs 16: 513-518, 1992).
Recently, however, l~ndl~r and Spicussa (PCT publication WO 92/02239) and Nho (PCT publication WO 92/08478) have been able to demonstrate slow or no methemoglobin formation in hemoglobin solutions stored under deoxygenated conditions without addition of exogenous rhemir~l red~lct~nt~ at room temperature for periods of up to 10 month~
The present invention is based on the surprising finrlin~ that hemoglobin undergoes significant modifications that can have physiological implications even prior to the appearance of significant quantities of methemoglobin. Furthermore, it has been discovered that there is a relationship between the amount of oxygen in a hemoglobin formulation and the amount of ascorbate required to stabilize the hemoglobin. In addition, it has been surprisingly discovered that certain ratios of hemoglobin, reducing agent and oxygen improve the stability of hemoglobin during storage.

SUMMARY OF THE INVENTION

The present invention relates to storage stable hemoglobin compositions co~ .ising partially deoxygenated hemoglobin solutions and less than 4 moles of reducing agent per mole of hemoglobin, prererably less than three moles of reducing agent per mole of hemoglobin, and more preferably less than two moles of reducing agent per mole of hemoglobin. The reducing agent is selected from the group consisting of dithionite, sodium borohydride and ascorbate, and is most ~erelably ascorbate. The partially deoxygenated hemoglobin solution contains less than 5000 parts per million of oxygen, more -W 096/3~889 PCTrUS96/06080 ~rere~ ably less than 500 parts per million of oxygen, most ~,~feldbly less than150 parts per million.
The storage stable hemoglobin composition of the instant invention is storage stable for at least three months, more ~lef~rably for at least six months, most ~efeldbly for at least one year. The compositions of the present invention can be stored at temperatures less than about 40~C, more ~rer~dbly at less than about 25~C or about 4~C or less, depending on the intended use and the desired storage con~i~ions. In addition, the present invention provides formulations comprising partially deoxygenated hemoglobin, less than 4 moles of reclucing agent per mole of hemoglobin, pharmaceutically acceptable carriers and chelating agents at pH between about 6.5 and 9.5, ~rereldbly pH 6.6 to 7.8, most ~rer~ldbly pH 6.8 to 7.6. Preferably the ch~l~hng agent is EDTA or DTPA, more ~,erelably the rh~olAtin~ agent is EDTA.
The present invention provides methods for the preparation of the storage stable hemoglobin composition of the invention comprising combining a reducing agent with partially deoxygenated hemoglobin solutions at ratios less than 4 moles of reducing agent per mole of hemoglobin. Methods for partial deoxyg~n~hon of a hemoglobin solution include gas-liquid contacting methods.
Additionally, the present invention provides systems for storage of hemoglobin solutions. The systems include the storage stable hemoglobin compositions of the present invention in suitable containers.

BRIEF DESCRIPTION OF THE FIGURES

c Figure 1 is a graph of the beta/di-alpha ratio on the y axis and theascorbate concentration in mM on the x axis. The beta/di-alpha ratios were deterrnined from reverse phase HPLC chromatograms. Samples were analyzed at 21 days after storage with 150 ppm oxygen (- o -), 1000 ppm oxygen (- ~ -), 5000 W O 96/34889 PCTrUS96/06n80 ppm oxygen (- ~ -) and 15000 ppm oxygen (- ~ -). Lower values for the beta/di-alpha ratio indicate a greater amount of modified beta globin.

DETAILED DESCRIPTION OF THE INVENTION

The present invention relates to storage stable hemoglobin solutions that are partially deoxygenated and contain less than 4 moles of reducing agent per mole of hemoglobin and methods of making such storage stable hemoglobin solutions.
Hemoglobin can be free in solution, or in solution in a naturally occurring or artificial cell (e.g. liposomes) and can be derived from natural, synthetic or recombinant sources. For example, sl~tlglltpr houses produce very large quantities of hemoglobin-contAining blood. Particular species or breeds ofAnimA1s which produce a hemoglobin especially suitable for a particular use can be sperificAlly bred in order to supply hemoglobin. Transgenic AnimAl~ can be produced that express non-endogenous hemoglobin (Logan, J.S. et al., PCT
application PCT/US92/05000). Human hemoglobin can be collected from outdated human blood that must be discarded after a certain ext,i~dLion date.
In addition to extraction from AnimAI sources, the genes encoding subunits of a desired naturally occurring or mutant hemoglobin can be cloned, placed in a suitable e~ression vector and inserted into an organism, such as a microorganism, animal or plant, or into cultured animal or plant cells or tissues. These organisms can be produced using standard recombinant DNA
techniques and the hemoglobin produced by these organisms can then be expressed and collecte~l as described, for example, in Hofrll~an, S.J and Nagai, K.
in U.S. Patent 5,028,588 and Hoffman, et al., WO 90/13645, both herein incorporated by re~elellce.
Purification of hemoglobin from any source can be accomplished using purification techniques which are known in the art. For e~ample, hemoglobin W 096/34889 PCTlUS96/06n80 can be isolated and purified from olltfi~te i human red blood cells by hemolysisof erythrocytes followed by chromatography (Bonhard, K., et al., U.s. Patent 4,439,357; Tayot, J.L. et al., EP Publication 0 132 178; Hsia, J.C., EP Patent 0 231 236 Bl), filtration (Rabiner, S.F. (1967) et al., T. Exp. Med. 126: 1127-1142; Kothe, N.
and Eichentopf, B. U.S. Patent 4,562,715), heating (Estep, T.N., PCT public~tionPCT/US89/014890, Estep, T.N., U.S. Patent 4,861,867), precipitation (Simmonds, R.S and Owen, W.P., U.S. Patent 4,401,652; Tye, RW., U.S. Patent 4,473,494) or combinations of these techniques (Rausch, C.W. and Feola, M., EP 0 277 289 Bl).
Recombinant hemoglobins produced in transgenic ~nim~ls have been purified by chromatofocusing (Townes, T.M. and McCune, PCT publication PCT/US/09624) while those produced in yeast and bacteria have been purified by ic~n exchange chromatography (Hoffman, S.J and Nagai, K. in U.S. Patent 5,028,588 and Hoffman, et al., WO 90/13645).
The hemoglobin can be rnc~iifi.o i by genetic or chemical means for particular uses either prior to, during or after purification. For example, the oxygem affinity can be altered by chemical moriifi~tion or by genetic modification of the hemoglobin through the introduction of a~lu~iate mutations. The hemoglobin can be chemically crosslinked~ or genetically linked or both chemically crossiinked and genetically linked to prevent the dissociation of the molecule into alpha/beta subunits (dimerizatiûn), prevent heme loss, or to increase the size of the molecule.
Hemoglobin solutions can be partially deoxygenated by any means known in the art. Treatment of hemoglobin solutions with an inert gas such as nitrogen or argon is one such approach. This can be accomplished using gas-liquid contacting techniques wherein oxygen is transported from a solution to a non-oxygen gas phase. Some options for gas-liquid contacting include: packed - columns, in which the non-oxygen gas passes upward while a solution trickles downward through a bed of packing; plate columns, similar to packed columns except that they contain a series of horizontal plates that cat.h the solution;

W 096/34889 PCTrUS96/06080 wetted-wall columns in which a solution falls as a film down a bank of vertical tubes; gas transfer membranes, wherein oxygen is transported across a thin membrane that retains liquid on one side and a non-oxygen gas on the other side; gas-sparged tanks, in which non-oxygen gas bubbles through a tank 5 containing the solution; cyclic pressurization, in which a vessel containing the solution is cyclically pressurized with a non-oxygen gas then vented to release the gas and induce bubbles to form in the solution; and liquid atomization, in which the solution is sprayed into a chamber co..l~i.ling a non-oxyg~ll gas.
Another approach to deoxy~;r-l~tion is liquid-liquid contacting 10 techniques, in which two immiscible liquids are mixed together, one of which contains no dissolved oxygen but in which oxygen readily dissolves. After the second liquid has absorbed the oxygen, the liquids can be separated by gravity or in a centrifuge.
A third approach to deoxygenation is sorption, in which solid particles 15 with a large internal surface area that adsorb dissolved oxygen, for example molecular sieves, are added to a solution. After sorption, the solid particles can be separated from the solution with a centrifuge or filter.
Of these techniques, a particularly useful technique is the use of a packed column, where the solution is deoxygenated by flowing an oxygenated 20 hemoglobin solution over the column, while flowing an inert gas countercurrent to the flow of the hemoglobin solution. The inert gas is any gas that does not bind at the heme group of a hemoglobin molecule, for example argon or nitrogen. In another embodiment, the solution is deoxygenated by repeatedly evacuating a hemoglobin solution and flushing or sweeping the 25 hemoglobin formulation with an inert gas, such as argon or nitrogen, until the desired residual oxygen concentration is obtained to produce a partially deoxygenated hemoglobin solution.
A partially deoxygenated hemoglobin solution is a hemoglobin solution that contains less than about 5,000 parts per million by volume (ppm) oxygen in , W Og6/3~889 PCT~US96/06080 the headspace. Residual oxygen in the hemoglobin solution is ~lerelably less than about 1000 ppm, more ~leferdbly less than about 500 ppm, and still more ~ler~Lably less than about 150 ppm. Residual oxygen in the headspace can be measured by any means known in the art including for example, sampling of 5 the headspace and measurement of the oxygen in the headspace using a suitably equipped gas chromatograph or zirconium-based detector. For example, the residual oxygen concentration can be del~ illed by sampling of the fill environment using a "MOCON" (Mocon, Minneapolis, MN) analyzer.
The fill environment is the environment in which the hemoglobin is 10 prepared for storage as described, for example, in Example 2. Fill environTn~ont~
include but are not limited to glove bags, glove boxes or any suitable environment in which the residual oxygen levels are controlled. The headspace above the h~moglobin formulation is consi~Pred to be in equilibrium with the fill environment. If there is no headspace in the 15 container, then the solution is considered to be in equilibriu~n directly with the fill environment. If the solution is placed into a cont~iner that has been evacuated prior to filling, then the hemoglobin is considered to be in equilibrium with the last gas with which it was in contact.
In addition to partially deoxygenated hemoglobin, the solutions of the 20 instant invention also contain reducing agents. Such reducing agents include but are not limited to dithionite, ferrous salts (for example ferrous pyrophosphate), sodium borohydride as well as other borohydrides, alpha tocopherol and ascorbic acid or salts therof. If the hemoglobin solution of the instant invention is a pharmaceutical, then the re~ucing agent is ~refeldbly a 25 pharmaceutically acceptable reducing agent. If the~ hemoglobin solution of the present invention is to be used in a non-pharmaceutical application, then the reducing agent can be any reducing agent, whether or not pharmaceutically acceptable. Preferably, the reducing agent is sodium ascorbate.

W 096/3~889 PCTrUS96/06080 The reducing agent can be added before or after partial deoxygen~hon Preferably, the reducing agent is added after the target residual oxygen level is achieved in the hemoglobin formlllAtion Although the reducing agent can be in a liquid or solid form, the reducing agent is especially useful when it is in a thoroughly deoxygenated concen~rated liquid solution. The amount of the reducing agent in the composihon of the instant il~v~nlion is less than 4 moles/mole of hemoglobin, more ~le~ldbly less than 2 moles of reducing agent/mole of hemoglobin.
The formulations can include other components in addition to the partially deoxygenated hemoglobin solution and one or more reducing agents.
The hemoglobin solution of the invention can be formulated in any composition suitable for pharmaceutical or non-pharmaceutical uses. For example, a parenteral therapeutic composition can comprise a sterile isotonic saline solution cont~ining between 0.001~ and 90~o ~w/v) hemoglobin.
Suitable composi~ons can also incdude 0 - 200 M of one or more buffers (for example, acetate, phosphate, citrate, bicarbonate, or Good's buffers). Salts such as sodium chloride, potassium chloride, sodium acetate, calcium dhloride, magnesium chloride can also be induded in the composi~ion~ of the invention at concentrations of 0-2 M. In addition, the compoci~ions of the invention can indude 0-2 M of one or more carbohydrates (for example, reducing carbohydrates such as glucose, maltose, lactose or non-reducing carbohydrates such as sucrose, trehalose, raffinose, mannitol, isosucrose or stadhyose) and 0-2 M of one or more alcohols or poly alcohols (sudh as polyethylene glycols, propylene glycols, dextrans, or polyols). The compc)sitiQn~ of the invention canalso contain 0.005 -1% of one or more surfactants and 0-200 ~LM of one or more chelating agents (for example, ethylenediamine tetraacetic acid (EDTA), ethylene glycol-bis (,B-aminoethyl ether) N,N,N',N'-tetraacetic acid (EGTA),o-phenanthroline, diethylamine triamine pentaacetic acid (DTPA also known as CA 02216382 1997-09-24 .

W 096/34889 PCTrUS96M6n80 pentaacetic acid) and the like). The compositions of the invention can also be at about pH 6.5 - 9.5.
In another emboAiln~nt, the composition cont~ins 0 - 300 mM of one or more salts, for example chloride salts, 0-100 mM of one or more non-reducing sugars, 0-100 mM of one or more buffers, 0.01 - 0.5% of one or more surf~t~nts, and 0-150 IlM of one or more ~ helAting agents. In a still further embodiment, the composition contains 0 - 150 mM NaCl, 0 - 10 mM sodium phosphate, and 0.01 - 0.1% surf~nt, and 0-50 ~LM of one or more ~h~l~ting agents, pH 6.6 - 7.8.Most ~rerelably, the hemoglobin-containing composition includes 5 mM
sodium phosphate, 150 mM NaCl, 0.025% to 0.08% polysorbate 80, and 25 ~M
EDTA, pH 6.8 - 7.6.
Additional additives to the formulation can include anti-bacterial agents, onco~ic pressure agents (e.g. albumin or polyethylene glycols) and other formulation acceptable salts, sugars and excipients known in the art. Each formulation according to the present invention can ~AAitic~n~lly comprise constituents including carriers, diluents, fillers, salts, and other materials well-known in the art, the selection of which depends upon the particular purpose to be achieved and the properties of such additives which can be readily determined by one skilled in the art.
The compositions of the present invention can be formulated by any method known in the art. Such formulation methods include, for example, simp]e mixing, seqll~nh~l addition, emulsification, diafiltration and the like.
Pharmaceutical compositions of the invention can be useful for, for example, subcutaneous, intravenous, or intramuscular injection, topical or oral administration, large volume parenteral solutions useful as blood substitutes, etc. I'harmaceutical compositions of the invention can be administered by any conventional means such as by oral or aerosol administration, by transdermal or mucus membrane adsorption, or by injection. Non-pharmaceutical compositions of the invention can be used as, for example, .eference standards W 096/34889 PCT~US96/0~080 for analytical insh~lme~t~tion needing such reference standards, reagent solutions, conhrol of gas content of cell cultures, for example by in vitro delivery of oxygen to a cell culture, and removal of oxygen from solutions.
In one embodiment, the composihons can be formulated for use in therapeutic applications. For example, the form~ tioI c of the present invention can be used in compositions useful as substihutes for red blood cells in any application that red blood cells are used. Such composihonç of the inct~nt invention formlll~t~1 as red blood cell substitutes can be used for the hreatment of hemorrhage where blood volume is lost and both fluid volume and oxygen carrying capacity must be replaced. Moreover, because the compositions of the instant invention can be made pharmaceutically acceptable, the formlll~tions of the instant invention can be used not only as blood substihutes that deliver oxygen but also as simple volume e~7~nd~rs that provide oncotic pressure due to the presence of the large hemoglobin protein molecule.
A typical dose of hemoglobin as a blood substitute is from 10 mg to 5 grams or more of extracellular hemoglobin per kilogram of patient body weight. Thus, a typical dose for a hllnn~n patient might be from a few grams to over 350 grams. It will be appreciated that the unit content of active ingredients contained in an individual dose of each dosage form need not in itself constitute an effective amount since the necessary effective amount could be reached by ~iministration of a plurality of ~llministrations as injections, etc.The 5~lection of dosage depends upon the dosage form nhli7~ri, the condition being treated, the particular purpose to be achieved according to the determination of the ordinarily skilled artisan in the field. "
Administration of extracellular hemoglobin can occur for a period of seconds to hours depending on the purpose of the hemoglobin usage. For example, as a blood delivery vehicle, the usual time course of ~iministration isas rapid as possible. Typical infusion rates for hemoglobin ;,olutions as blood W 096/34889 PCT~US96/06080 replacPmPnts can be from about 100 ml to 3000 ml/hour. However, when used to stimulate hPm~topoie5is, administration can last only seconds to five minutes and therefore ~lmini~;tration rates can be slower because the dosage of hemoglobin is much smaller than dosages that can be required to treat 5 hemorrhage.
In a futher embo~limPnt, the formulation of the instant invention can be used to treat ~nPrni~, both by providing ~ itional oxygen carrying capacity in apatient that is suffering from anemia, and by stimulating hPm~topoiesis. In addition, because the distribution of the hemoglobin in the vasculature is not 10 limite~l by the size of the red blood cells, the hemoglobin of the present invention can be used to deliver oxygen to areas that red blood cells cannot penetrate. These areas can include any tissue areas that are located downstream of obstructions to red blood cell flow, such as areas downLstream of thrombi, sid~le cell occlusions, arterial ocdusions, angioplasty balloons, surgical 15 instrllrnPntAtion or any tissues that are suffering from oxygen starvation or are hypoxic, and the like. ~ iffo~lly~ any types of tissue ischemia can be treated using the cros~;linkefl hemoglobins of the instant ill~,el~Lion. Such tissue ischemias include, for example, stroke, emerging stroke, tr~n~;ient isl~l PTnic attacl s, myocardial stunning and hibern~fion, acute or unstable ~ngin~, 20 emerging angina, infarct, and the like. Because of the broad distribution in the body, the hemoglobins of the instant invention can also be used tc deliver drugs and for in vivo imaging.
The compositions of the instant invention can also be used as replacement for blood that is removed during surgical procedures where the 25 patient's blood is removed and saved for reinfusion at the end of surgery or during recovery (acute normovolemic hemodilution or hemoaugmentation).
- Because the hemoglobin of the instant invention can bind nitric oxide and other non-oxygen ligands as well as oxygen, the form~ ion~i of the instant invention are also useful for the binding or delivery of nitFic oxide or non-WO 9613~889 PCT~US96/06080 oxygen ligands. These non-oxygen ligands can be bound or delivered both in vivo or in vitro. For example, the hemoglobin of the instant invention can be used to remove excess nitric oxide from a living system. Excess nitric oxide has t been implicated in conditions r~nging from hypotension to septic shock. In these cases, the hemoglobin of the present invention can be used to remove excess nitric oxide or to remove any other ligand that is found in toxic excess and that can be bound to the hemoglobin. Likewise, nitric oxide or other non-oxygen lig~ntls can be delivered to a system to alleviate a ~ise~ce condition. For example, nitric oxide could be delivered to the v~cr~ re to treat hypertension. Other therapeutic uses of the instant invention can include drug delivery and in vivo imaging.
The composition of the present invention can also be used for a number of in vitro applications. For example, the delivery of oxygen by the composition of the instant invention can be used for the ~nh~nc~ment of cell growth in cell culture by mairlf~ining oxygen levels in vifro. Moreover, the hemoglobin of the instant invention can be used to remove OXY~1L from solutions requiring the removal of oxy~,en, and as rererence standards for analytical assays and instrumentation.
The compositions of the instant invention can be stored at temperatures less than 40~C for periods of 12 moTlths or more. Preferably, the hemoglobin of the present invention can be stored at 25~C for periods of 12 months or more.
More ~le~dbly the solution can be stored at 25~C for periods of at least 6 months, most ~ref~ably the solution of the instant invention can be stored at 25~C for at least three morlths. In another embo~lim~nt~ the solutions of the instant invention can be stored at 4~C for at least 6 months, more preferably 12months. In a further embodiment, the solutions of the instant invention can be stored at temperatures less than 4~C for at least three month.s.
The hemoglobin solutions of the instant invention can be stored in oxygen impermeable containers, for example, stainless steel tanks, oxygen W 096/3~889 PCT/US96/06080 impermeable plastic bags, or plastic bags overwrapped with low oxygen permeably plastic bags wherein an oxygen scavenger is placed between the internal plastic bag and the overwrapped plastic bag. In another embodiment, the storage stable hemoglobin solutions can be stored in oxygen permeable or 5 oxygen impermeable contAinP-s in an oxygen controlled environment. Such oxygen controlled environm~nts can indude, for example, glove boxes, glove bags, incubators and the like. Preferably the oxygen rontPnt of the oxygen controlled environment is low relative to atmospheric oxygen concenhrations.
Stability of the hemoglobin solutions of the instant invention can be 10 deLel~ .ed by any means accepted in the art. Generally, stability Qn be determined by the measurement of degradation of the hemoglobin, sudh as the formation of oxi~lAtion, proteolytic or deamidation products, changes in molecular weight distribution, changes in potency, changes in filnch( nAlity, increases in insoluble matter sudh as aggregates or mo~lifi~Ation of the product15 due to the presence of excipients, such as non-enzymatic glycation. In A~1tlihnn, stability Qn be determined as a loss of sterility or changes in ~onc.ontration due to for example, volahli7Ation, adsorption, chemical modification and the like.
Preferably, stability of hemoglobin solutions is deLell~ulled by measurement of functionAlity, measurement of oxidation products, changes in molecular 20 weight distribution and increases in degrA~iAtion products. Such degradation can be monitored by changes in the ratio of beta globin to alpha globin _s described, for example, in Example 1. Accordingly, storage stable hemoglobin solutions are those solutions of hemoglobin that show less than 10%
hemoglobin degradation, less than 10% change in molecular weight 25 distribution, or contain less than 5% methemoglobin. Storage stable solutions can also show any combination of these characteristics. The hemoglobin comprising the storage stable solution can have the filncticnAlity nec.ossAry for a specific application. For example, if the storage stable hemoglobin of the W O 96t3~889 PCT~US96/06080 present invention is to be used as a blood substitute, then it should have a Psogreater than about 27 mm Hg, or have an nma7~ greater than about 1.7.

EXAMPLES
The following examples are provided by way of describing specific embodiments of the present invention without int~n-ling to limit the scope of the invention in any way.

STABILITY MEASUREMENT TECHNIQUES

Measurement of molecular weight distribution The molecular weight distribution of the hemoglobin composition of the instant invention was determined as follows. Hemoglobin solutions were diluted to approximately 4 mg/ml concentrations in 5 mM sodium phosphate, 150 mM NaCl, pH 7.6. Aliquots (25 ~Ll) were chromatographically separated using a Pharmacia "SUPEROSE" 12 (Piscataway, New Jersey) size exdusion column. The columns were eluted with the same buffer as the dilution buffer at a flow rate of 0.5 ml/min. Absorbance was monitored at 280 nm.

Measurement of globin composition The degradation of the hemoglobin molecule can be determined by monitoring modification of the beta globin. A simple method for the quantitation of beta globin modification is by determination of changes in relative globin composition (i.e. beta globin cont~nt versus alpha or di-alpha globin content). Either the alpha globin peak area or the di-alpha globin peak can be used in the analysis. Use of the a~ro~liate peak will depend on the composition of the hemoglobin under examination.
The globin composition (beta globin and di-alpha globin) of the hemoglobin was determined as follows. Heme was removed from hemoglobin solutions by precipitating with a cold acid acetone solution (0.6% HCl/acetone).
-W 096/34889 PCTrUS96/06080 Hemoglobin was diluted to approximately 10 ~lg/lll with HPLC grade water. 100 ~11 of this diluted hemoglobin solution was mixed with the cold acid-acetone mixture, allowed to precipitate and microcentrifuged to separate the fractions.
The supernatant was aspirated and discarded; the pellet was dried with a stream J 5 of argon and stored at -20~C until chromatographic analysis.
HPLC was performed using a Zorbax C3 HPLC analytical c~ mn (MAC-MOD Analytical, Inc., (-h~ Ford, Pennsylvania). Prior to analysis, the pellet was resuspended in 0.5 ml of 0.1% trifluoroacetic acid (TFA) to yield a final concentration of approximately 2 mg/ml. Any residual undissolved material was removed by spinning the sample for 10 minllt~ in a microcentrifuge prior to application on the analytical column. Approximately 100 llg of protein were separated on the Zorbax column using the following separation regime: 35%
solvent B for five minutes, then linear ramp to 49% solvent B during the next 45 minutes, where solvent A was 0.1%TFA in ~LC-grade water and solvent B
was 0.1% TFA in acetonitrile. The flow rate for the separation was 1 ml/min.
Absorbance was monitored at 215 nm.
The area of the beta polypeptide peak changed signihr~ntly under certain concli~ons. For example, the area of the beta peak for hemoglobin stored under high oxygen conditions in the presence of increasing ascorbate conr~ntrations had decreased markedly during 21 days of storage. The decrease in the area of the beta peak resulted in a reduction of the ratio of the beta globin peak area to the di-alpha globin peak area. Because of minor differences in the initial di-alpha content of a given hemoglobin solution, the ratio of the area of the beta peak to the di-alpha peak provided a measure of the degradation of the hemoglobin solutions that could be used for comparison of the effectiveness of different storage con~ition~ for different hemoglobin solutions. As shown in Table 1, solutions prepared according to Example 2 and analy~d for the beta/di-alpha peak ratio as described above appeared to be stable at beta/di-alpha ratios of greater than 0.9 if methemoglobin formation was control'ed. A beta/di-alpha ratio of 0.9 is considered to be equivalent to approximately 10%
degradation of hemoglobin.

~50 and nttlnr determination P50 and nmaX~ f~lnctio~Al properties of the hemoglobin, were determined by oxygen equilibrium binding experiments using a HEMOX instrument (TCS, Inc.) as described in Hoffman and Nagai, US Patent 5,028,588, herein incorporated by re~~ ce. Pso and nn,aX were determined at 37 ~C, 50 mM
HEPES, 100 mM Cl-, pH 7.4.

A~themoglobin concentr~tion Methemoglobin is hemoglobin wherein one or more of the irons of the heme prosthetic groups are in the Fe+3 (ferric) oxidation state. The measurement technique for methemoglobin described herein m~Ac-lres the oxi(lA~ion state of individual heme irons. Thus, the reported ~er~elilage of methemoglobin reflects the percentage of hemes that are oxidized in the hemoglobin sample.
Five microliters of hemoglobin solutions were added to 500 ~Ll of 0.1 M
Tris, pH 8Ø 200 111 of the diluted hemoglobin solution was then added to 2.8 ml of 0.1 M Tris, pH 8.0 in a 4.5 ml cuvette for a final dilution of 1:1500. Theoxygenated sample (Hb) was then analy~d by spectrophotometry in a Hewlett-Packard model ~ 8452A spectrophotometer. Absorbances at 436, 425, 420, 404, 400 nm were collected and stored in a data storage system. The cuvette was then removed from the spectrophotometer and sparged with carbon monoxide two times for 15 seconds each time. The cuvette was inverted 5 times between each sparge. The sample was then re-inserted into the spectrophotometer, and a second set of spectra were collected that co~e~onded to carbonmonoxy hemoglobin (HbCO). The cuvette was then again removed from the spectrophotometer and 30 ~1 of 0.1M KCN in 0.1 M Tris, pH 8.0 was added to the sample. The sample was then inverted three times, allowed to incubate for W 096/3.~889 PCT~US96/06080 5 minutes, and re-inserted into the spectrophotometer for a final speckophotometric analysis (HbCN). The percent methemoglobin was then s c~ ted as follows:

~ HbCN HbCN Hb Hb]
~A42s - A404 ] --[ A42s--A~04 % Met~lb - HbcO Hbc~_ Hb Hb ] _ HbCN] Hb Hb] ~100 [A420 -A436 [A42o- A436 + [A425 A~04 - [A425- A404 where A = the absorbance at the susbcripted wavelength for the superscripted hemoglobin species.

E~ICAMPLE 2 Preparation of Hemogiobin Solutions for Stab~ity Studies Hemoglobin was expressed, prepared and purifiied as described in co-owned PCT patent application number, PCT/US94/13034, filed November 14, 1994, ~ntitlerl "Purific~fic-n of Hemoglobin", incorporated herein by reference.The hemoglobin was then concentrated by diafiltration to a concentration of 100 mg/ml and polysorbate 80 was added to a final concenh-ation of 0.03%
(w/v). The hemoglobin solution was then deoxygenated by flowing oxygen-free nitrogen gas over the hemoglobin solution for approximately 2 hours in a round bottomed flask. The solution was deoxygenated with nitrogen and then equilibrated with the oxygen mixture dhosen for the study.
Ascorbate was prepared as a 0.5 M stodk solution. The ascorbate solution was then deoxygenated by repeated evacl~hon~ of the stod< solution and flushing with oxygen-free nitrogen gas four to five cydes. The ascorbate solutions were made up freshly for eadh experiment described herein. Once the ascorbate solution was prepared, it was moved into a glove bag (the "fill environment") along with the deoxygenated hemoglobin solution and the glove bag was equilibrated to the required residual level of oxygen in the headspace of the glove bag by repeated evacuations and flushing with the a~p,o~riate oxygen/nitrogen W 096/34889 PCTrUS96/06n80 mixture. The residual oxygen concentration in the glove bag was determined using a "MOCON" apparatus as described above. After equilibration of the glove bag, the ascorbate and the hemoglobin solution were opened, and ascorbate was added to final rrnC~ntrations of 0.5 to 5 mM. The hemoglobin solutions 5 containing ascorbate were aliquoted into 2 ml glass vials as 0.5 ml aliquots. The vials were capped with gray butyl rubber sLo~ and crimp sealed. The solutions were removed from the glove bag and stored in temperature controlled incubators at either 4~C or 25~C under ambient gas ron~iitions.
Solutions were stored for up to three months. Vials were withdrawn 10 from the stored samples at a~lo~iate time points for given stability test.
These tests included, reverse phase HPLC analysis for the detern~inAtic-n of thebeta and di-alpha r( ntPnt~ molecular weight distribution by high performance size exclusion chromatography (HP-SEC), fi]nctio~Ality del~...i..Ations using P50 and nmaX values, and methemoglobin concr-ntration.

Oxygen/Ascorbate Titration Studles: effect on beta/di-alpha ratio and l"t~ ",oglobin COllC~I I lrd tion To de~ e the effect of ascorbate eonc~ntration on the stability of 20 hemoglobin over time, solutions of hemoglobin were prepared as described above. These solutions contAine~1 150, 1000, 5000 and 15000 ppm oxygen in the headspace and either 0.5, 1, 2 and 5 mM conc~nt~ations of ascorbatc in the solution (ratios of 0.3:1, 0.6:1, 1.3:1 and 3.2:1 ascorbate to hemoglobin molar ratios respectively). Solutions were stored for 3 weeks at 4~C. The beta to di-25 alpha ratio and the percentage of methemoglobin in the solutions wasdetermined at the end of the storage period. The greatest change in the beta/di-alpha ratio was observed in samples con~Aining high levels of both ascorbate and residual oxygen, while the greatest increase in percentage methemoglobin was observed in forml.lAtionci cont~ining oxygen and low ascorbate (Table 1).
30 At low residual oxygen levels (1000 ppm and lower) there was little change in CA 022l6382 l997-09-24 W O96/31889 PCTrUS96/n6~80 the beta/di-alpha ratio whether or not there was ascorbate in the form ll~ticn However, if there was no ascorbate in the formulation, there were high levels of methemoglobin in the formlllAtion at the end of the storage period. At high resid!ual oxygen levels (5000 and 15000 ppm), the high ascorbate form~ tion~
5 (ascorbate greater than approximately 0.5 mM) showed greater changes in the beta/di-alpha ratio (see Figure 2 and Table 1) than the low ascorbate formulations. In addition, there was appreciable formAtion of methemoglobin in high residual oxygen forntl~lAtionc It is of note that at the end of the storage period, methemoglobin was m~tintAined at low levels except in the presence of greater than 5000 ppm o~yg~ll and less than 1 mM ascorbate. Thus even when there was no appreciable formation of methemoglobin in the hemoglobin formulation, there was modification of the polypeptide subunits.

Table 1. Beta/di-alpha ratios and % methemoglobin in hemoglobin solutions stored for 21 days at 4~C.

150 p~m O2 15000 ppm ~2 beta/di-alpha %~ uLillbeta/di-alpha~/dll~ loL~", 0 mM ascorbate 1.00 19.18 0.97 39.82 0.5 mM ascorbate 0.99 1.48 0.88 46.21 1 mM ascorbate 1.00 1.00 0.82 45.06 2 mM ascorbate 0.98 0.7 0.78 3.34 5 mM ascorbate 0.99 0.54 0.72 1.50 E~CAMPLE 4 Oxygen/Ascorbate Titration Studies: effect on functionality To deterrnine the effect of ascorbate conc~ntration on the functionality of hemoglobin over time, solutions of hemoglobin were prepared as des~ibed above in Example 4. The fllnction~ y of the hemoglobin in the solution was determined at the end of the three week storage period by .he determination of W O 96/34889 PCTrUS96106080 P50 and nmaX as described above. There were minimal differences in the Pso and nmaX values at the 150 and 1000 ppm r.o~irlllAl oxygen levels for the different ascorbate concentrations (Table 2). However, at 5000 and 15000 ppm residual oxygen concentrations, higher ascorbate cor l ~ntrations were 5 accompanied by iricreases in Pso values. Fur~ermore, at 15000 ppm residual oxy~,elL concentration, the nlI~aX decreased with increasing ascorbate conc~nh ation (Table 2).
Table 2.
Headspace Oxygen Concentration 150 ppm 1000 ppm 5000 ppm ¦ 15000 ppm Ascorb~te (mM) P50nmaX P50 nmax P50 nmax P50 nmaX
0 33.42.14 32.2 2.07 32.2 1.87 28.5 1.7 0.5 - - 34.7 2.16 33.0 1.79 33.52.18 34.0 2.16 34.8 1.89 33.0 1.51 2 - - 34.6 2.16 35.0 1.92 33.82.11 33.7 2.22 35.4 1.86 37.3 1.49 Long term, room tt~ dl~lre storage of partially deoxygenated/~orbate conld",i"~
hemo~l~b, form~ tions Four different deoxygenated formulations, all contAinin~ 100 mg/ml hemoglobin and 2mM ascorbate and prepared as described in Example 2, were storedfor 3 months at 25~C. The formulations all contained 150 mM NaCl, 5 mM sodium phosphate, 2 mM ascorbate, 0.03% polysorbate 80 (standard formulation) and differed 20 in the following manners:
(1) standard forml~lAhf~n, pH 6.75 (2) standard formulation, pH 7.21 W 096/34889 PCTrUS96/06080 (3) standard form~ ti~n, 25 IlM EDTA, pH b.75 (4) standard forrn~ tic-n, 25 ~M EDTA, pH 7.21 Throughout the storage period, and at the completion of the 3 month storage 5 period, samples were analyzed for methemoglobin cc l~~l~(, changes in molecular weight measured as ~o high molecular weight hemoglobin (HMWHb), beta/di-alpha ratio, aggregate formation by both dynamic light scattering and light obscuration techniques and fimction~lity (Pso and nmaX). Atthe conclusion of the storage period there had been no ~ lini~-~lly relevant 10 change in any of the parameters monitored throughout the study period (Table 3).

Table 3.
Formulation #1 Formulation #2 Formulation #3 Formulation #4 Initial 3 months Initial 3 months Initial 3 months Initial 3 months % metE~b 4.66 1.24 3.43 1.03 3.37 1.41 1.57 0.811 %

HMWHb 1.67 2.16 1.81 2.421.67 2.4 1.73 2.53 a 1.05 0.9410.99 0.962 1.05 0.954 1.02 0.966 DLS (nm) 6.4 7.1 6.5 9.756.2 8 6.5 6.2 p50 30.9933.6231.05 34.41 3Z.0234.93 34.88 35.08 nmAx 2.23 2.02 2.19 1.942.171.98 2.35 1.94 The foregoing description of the invention is exemplary for purposes of illustration and explanation. It will be apparent to those skilled in the art that 20 changes and modifications will be possible without departing from the spirit and the scope of the invention. It is int~n~ed that the following claims be inleL~reLed to embrace all such changes and modifications.

Claims

What is claimed is:

1. A storage stable hemoglobin composition comprising a partially deoxygenated hemoglobin solution and less than 4 moles of reducing agent per mole of hemoglobin to form said storage stable hemoglobin solution.

2. The composition of claim 1 wherein the partially deoxygenated hemoglobin solution contains less than 5000 parts per million of oxygen.

3. The composition of claim 2 wherein the partially deoxygenated hemoglobin solution contains less than 1000 parts per million of oxygen.

4. The composition of claim 3 wherein the partially deoxygenated hemoglobin solution contains less than 500 parts per million of oxygen.

5. The composition of claim 4 wherein the partially deoxygenated hemoglobin solution contains less than 150 parts per million of oxygen.

6. The composition of claim 1 wherein the reducing agent is selected from the group consisting of dithionite, sodium borohydride, and ascorbic acid or salts thereof.

7. The composition of claim 6 wherein the reducing agent is ascorbic acid or salts thereof.

8. The composition of claim 1 wherein the reducing agent is less than 3 moles of reducing agent per mole of hemoglobin.

9. The composition of claim 8 wherein the reducing agent is less than 2 moles of reducing agent per mole of hemoglobin.

10. The composition of claim 1 wherein the storage stable hemoglobin is storage stable for at least one year.

11. The composition of claim 1 wherein the storage stable hemoglobin is storage stable for at least six months.

12. The composition of claim 1 wherein the storage stable hemoglobin is storage stable for at least three months.

13. The composition of claim 1 wherein the storage stable hemoglobin is storage stable up to 40°C.

14. The composition of claim 13 wherein the storage stable hemoglobin is storage stable at about 25°C.

15. The composition of claim 11 wherein the storage stable hemoglobin is storage stable at about 4°C.

16. The composition of claim 12 wherein the reducing agent is ascorbate and the partially deoxygenated hemoglobin solution contains less than about 150 ppm oxygen.

17. A method of making a storage stable hemoglobin composition comprising combining a partially deoxygenated hemoglobin solution with less than 4 moles of reducing agent per mole of hemoglobin.

18. The method of claim 17 further comprising partially deoxygenating a hemoglobin solution.

19. The method of claim 18 wherein the deoxygenation is by gas-liquid contacting methods.

20. The composition of claim 1 further comprising a pharmaceutically acceptable carrier.

21. The composition of claim 20 wherein said carrier contains at least one pharmaceutically acceptable excipient.

22. The composition of claim 1 further having pH between about 6.5 and about 9.5.

24. The composition of claim 18 having pH between about 6.6 and about 7.8.

25. The composition of claim 14 having pH between about 6.8 and about 7.6.

26. The composition of claim 1 further comprising a chelating agent.

27. The composition of claim 26 wherein the chelating agent is selected from the group consisting of EDTA and DTPA.

28. The composition of claim 27 wherein the chelating agent is EDTA.

29. A system for the storage of storage stable hemoglobin solutions comprising:
a partially deoxygenated hemoglobin solution containing less than 4 moles of reducing agent per mole of hemoglobin; and a container for storage of said partially deoxygenated hemoglobin solution.
CA002216382A 1995-05-02 1996-05-01 Storage stable hemoglobin solutions Abandoned CA2216382A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/433,896 US5929031A (en) 1995-05-02 1995-05-02 Storage stable hemoglobin solutions
US08/433,896 1995-05-02

Publications (1)

Publication Number Publication Date
CA2216382A1 true CA2216382A1 (en) 1996-11-07

Family

ID=23721974

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002216382A Abandoned CA2216382A1 (en) 1995-05-02 1996-05-01 Storage stable hemoglobin solutions

Country Status (7)

Country Link
US (1) US5929031A (en)
EP (1) EP0826004B1 (en)
JP (1) JPH11507016A (en)
AT (1) ATE203546T1 (en)
CA (1) CA2216382A1 (en)
DE (1) DE69614105T2 (en)
WO (1) WO1996034889A1 (en)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6242417B1 (en) * 1994-03-08 2001-06-05 Somatogen, Inc. Stabilized compositions containing hemoglobin
US6271351B1 (en) 1995-03-23 2001-08-07 Biopure Corporation Method for preserving a hemoglobin blood substitute
US6288027B1 (en) 1995-03-23 2001-09-11 Biopure Corporation Preserving a hemoglobin blood substitute with a transparent overwrap
US6610832B1 (en) 1995-03-23 2003-08-26 Biopure Corporation Preserving a hemoglobin blood substitute with a transparent overwrap
US5981710A (en) * 1997-07-21 1999-11-09 Baxter International, Inc. Therapeutic hemoglobin composition having isotropically increased size
US6018035A (en) * 1997-07-21 2000-01-25 Baxter International Inc. Reagents for isotropic size enhancement of a peptide, protein, nucleotide or other substrate
US6204254B1 (en) 1997-09-12 2001-03-20 Baxter International, Inc. Biocompatible surfaces and a method for their preparation
ATE305013T1 (en) * 1999-07-01 2005-10-15 Int Reagents Corp AGENT FOR STABILIZING HEMOGLOBINS
JP3466516B2 (en) * 1999-09-07 2003-11-10 科学技術振興事業団 Stable oxygen storage solution
US6894150B1 (en) * 1999-10-01 2005-05-17 Ross Walden Tye Non-pyrogenic, endotoxin-free, stroma-free tetrameric hemoglobin
US7449339B2 (en) * 1999-11-23 2008-11-11 Nir Diagnostics Inc. Spectroscopic method and apparatus for total hemoglobin measurement
US6949384B2 (en) * 2001-12-21 2005-09-27 Spectromedical Inc. Method for monitoring degradation of Hb-based blood substitutes
FR2809624B1 (en) * 2000-05-31 2002-08-02 Centre Nat Rech Scient USE AS A BLOOD SUBSTITUTE OF A HIGH MOLECULAR WEIGHT EXTRACELLULAR HEMOGLOBIN
US6974447B2 (en) * 2001-04-17 2005-12-13 Baxter International Inc. High gas barrier receptacle and closure assembly
MXPA03009555A (en) * 2001-04-18 2004-12-06 Northfield Lab Flexible container system for storage of stabilized hemoglobin solutions.
US7747315B2 (en) * 2002-01-15 2010-06-29 Board Of Regents, The University Of Texas System Methods and compositions to reduce scattering of light during therapeutic and diagnostic imaging procedures
US20050260259A1 (en) * 2004-04-23 2005-11-24 Bolotin Elijah M Compositions for treatment with glucagon-like peptide, and methods of making and using the same
US7138105B2 (en) * 2002-02-27 2006-11-21 Pharmain Compositions for delivery of therapeutics and other materials, and methods of making and using the same
US7635463B2 (en) 2002-02-27 2009-12-22 Pharmain Corporation Compositions for delivery of therapeutics and other materials
JP2006502116A (en) * 2002-07-12 2006-01-19 メダレックス, インク. Methods and compositions for preventing oxidative degradation of proteins
US7223604B1 (en) * 2002-09-27 2007-05-29 Science & Technology Corporation @ Unm Methods and kits for the detection of erythrocytes
EP1592437A4 (en) * 2003-01-29 2007-12-26 Northfield Lab Polymerized hemoglobin solutions having reduced amount of tetramer and method for preparing
JP2006164312A (en) * 2004-12-02 2006-06-22 Hitachi Ltd Semiconductor device and magnetic recording and reproducing device using same
WO2006096774A2 (en) 2005-03-07 2006-09-14 Sangart, Inc. Composition and methods for delivering carbon monoxide (co) and nitric ozide (no) co to tissue using heme proteins as carriers
US20090004159A1 (en) * 2006-01-24 2009-01-01 The Board Of Trustees Of The University Of Illinoi Polymerized Hemoglobin Media and Its Use in Isolation and Transplantation of Islet Cells
JP2009524436A (en) * 2006-01-24 2009-07-02 ノースフィールド ラボラトリーズ、インコーポレイテッド Polymerized hemoglobin medium and its use in isolation and transplantation of islet cells
US7494974B2 (en) * 2006-10-24 2009-02-24 Ikor, Inc. Carboxymethylated cross-linked tetrameric hemoglobin
US7504377B2 (en) * 2006-10-23 2009-03-17 Ikor, Inc. Nitric oxide-blocked cross-linked tetrameric hemoglobin
JP2008195656A (en) * 2007-02-14 2008-08-28 Nipro Corp Artificial oxygen-carrying substance preparation
US8609815B2 (en) 2010-09-02 2013-12-17 Sangart, Inc. Methods for preparing stable deoxygenated PEG-hemoglobin conjugate solutions comprising an antioxidant
US9199026B2 (en) * 2011-01-07 2015-12-01 Somerset Group Enterprises, Inc. Modular extracorporeal systems and methods for treating blood-borne diseases
WO2013106443A1 (en) 2012-01-09 2013-07-18 Somerset Group Enterprises, Inc. Modular extracorporeal systems and methods for treating blood-borne diseases
US9763889B2 (en) * 2015-06-29 2017-09-19 Billion King International Ltd. Oral delivery system for hemoglobin based oxygen carriers
US10052290B2 (en) * 2016-02-04 2018-08-21 Billion King International Ltd. Enteric-coated hemoglobin multiparticulate for oral delivery of hemoglobin based oxygen carriers
WO2021204948A1 (en) * 2020-04-09 2021-10-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions to determine the quality of red blood cell units

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3144705C2 (en) * 1981-11-11 1983-12-08 Biotest-Serum-Institut Gmbh, 6000 Frankfurt Process for the production of a storage-stable, cross-linked hemoglobin preparation with high oxygen transport capacity, as well as the hemoglobin preparation produced by this process
US4727027A (en) * 1983-05-02 1988-02-23 Diamond Scientific Co. Photochemical decontamination treatment of whole blood or blood components
US4861867A (en) * 1988-02-03 1989-08-29 Baxter International, Inc. Purified hemoglobin solutions and method for making same
US5234903A (en) * 1989-11-22 1993-08-10 Enzon, Inc. Chemically modified hemoglobin as an effective, stable non-immunogenic red blood cell substitute
WO1992002239A1 (en) * 1990-08-06 1992-02-20 Baxter International Inc. Stable hemoglobin based composition and method to store same
US5352773A (en) * 1990-08-06 1994-10-04 Baxter International Inc. Stable hemoglobin based composition and method to store same
AU9067791A (en) * 1990-11-20 1992-06-11 Enzon, Inc. Method of enhancing long-term storage stability of hemoglobin products
SE9301581D0 (en) * 1993-05-07 1993-05-07 Kabi Pharmacia Ab PROTEIN FORMULATION

Also Published As

Publication number Publication date
AU708264B2 (en) 1999-07-29
DE69614105T2 (en) 2002-03-21
EP0826004B1 (en) 2001-07-25
US5929031A (en) 1999-07-27
EP0826004A1 (en) 1998-03-04
AU5852096A (en) 1996-11-21
ATE203546T1 (en) 2001-08-15
JPH11507016A (en) 1999-06-22
DE69614105D1 (en) 2001-08-30
WO1996034889A1 (en) 1996-11-07

Similar Documents

Publication Publication Date Title
EP0826004B1 (en) Storage stable hemoglobin solutions
EP0714407B1 (en) Composition and methods using nitroxides to avoid oxygen toxicity
EP1863503B1 (en) Composition for delivering carbon monoxide (co) and nitric ozide (no) co to tissue using heme proteins as carriers
US11845785B2 (en) Compositions and methods for the treatment of carboxyhemoglobinemia
US6160098A (en) Method for control of functionality during cross-linking of hemoglobins
AU708264C (en) Storage stable hemoglobin solutions
CA2231245A1 (en) Hemoglobin mutants that reduce heme loss
WO1992002239A1 (en) Stable hemoglobin based composition and method to store same
US7285379B2 (en) Artificial oxygen carrier and production method thereof
WO1999018979A1 (en) Storage-stable hemoglobin composition
US8609815B2 (en) Methods for preparing stable deoxygenated PEG-hemoglobin conjugate solutions comprising an antioxidant
AU715073C (en) Hemoglobin mutants that reduce heme loss
US6812207B1 (en) Hemoglobin mutants that reduce heme loss
Winslow et al. Artificial Cells, Blood Substitutes, and Immobilization Biotechnology. Volume 22, Number 3, 1994.
CA2309236A1 (en) Cross-linked hemoglobins for transport and delivery of nitric oxide
KR20020016954A (en) Hemoglobin Composition

Legal Events

Date Code Title Description
FZDE Discontinued